These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

48 related articles for article (PubMed ID: 1486543)

  • 21. Pravastatin reduces restenosis two years after percutaneous transluminal coronary angioplasty (REGRESS trial).
    Mulder HJ; Bal ET; Jukema JW; Zwinderman AH; Schalij MJ; van Boven AJ; Bruschke AV
    Am J Cardiol; 2000 Oct; 86(7):742-6. PubMed ID: 11018193
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pravastatin reduces restenosis after coronary angioplasty of high grade stenotic lesions: results of SHIPS (SHIga Pravastatin Study).
    Nakamura Y; Yamaoka O; Uchida K; Morigami N; Sugimoto Y; Fujita T; Inoue T; Fuchi T; Hachisuka M; Ueshima H; Shimakawa H; Kinoshita M
    Cardiovasc Drugs Ther; 1996 Sep; 10(4):475-83. PubMed ID: 8924063
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Functional evaluation of lipid-lowering therapy by pravastatin in the Regression Growth Evaluation Statin Study (REGRESS).
    Aengevaeren WR; Uijen GJ; Jukema JW; Bruschke AV; van der Werf T
    Circulation; 1997 Jul; 96(2):429-35. PubMed ID: 9244208
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Asp9 Asn mutation in the lipoprotein lipase gene is associated with increased progression of coronary atherosclerosis. REGRESS Study Group, Interuniversity Cardiology Institute, Utrecht, The Netherlands. Regression Growth Evaluation Statin Study.
    Jukema JW; van Boven AJ; Groenemeijer B; Zwinderman AH; Reiber JH; Bruschke AV; Henneman JA; Molhoek GP; Bruin T; Jansen H; Gagné E; Hayden MR; Kastelein JJ
    Circulation; 1996 Oct; 94(8):1913-8. PubMed ID: 8873668
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of pravastatin on progression and regression of coronary atherosclerosis and vessel wall changes in carotid and femoral arteries: a report from the Regression Growth Evaluation Statin Study.
    de Groot E; Jukema JW; van Boven AJ; Reiber JH; Zwinderman AH; Lie KI; Ackerstaff RA; Bruschke AV
    Am J Cardiol; 1995 Sep; 76(9):40C-46C. PubMed ID: 7572685
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evidence for a synergistic effect of calcium channel blockers with lipid-lowering therapy in retarding progression of coronary atherosclerosis in symptomatic patients with normal to moderately raised cholesterol levels. The REGRESS Study Group.
    Jukema JW; Zwinderman AH; van Boven AJ; Reiber JH; Van der Laarse A; Lie KI; Bruschke AV
    Arterioscler Thromb Vasc Biol; 1996 Mar; 16(3):425-30. PubMed ID: 8630669
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The influence of angiographic endpoints on the outcome of lipid intervention studies. A proposal for standardization. REGRESS study group.
    Jukema JW; van Boven AJ; Zinderman AH; Bal ET; Reiber JH; Bruschke AV
    Angiology; 1996 Jul; 47(7):633-42. PubMed ID: 8686956
    [TBL] [Abstract][Full Text] [Related]  

  • 28. On the statistical modelling of coronary arteriographic data: dynamics of coronary atherosclerosis related to systemic and focal parameters. REGRESS Study Group. Regression Growth Evaluation Statin Study.
    Zwinderman AH; Jukema JW; van Boven AJ; Reiber JH
    Stat Med; 1997 Dec; 16(24):2829-41. PubMed ID: 9483717
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design and recruitment in the United States of a multicenter quantitative angiographic trial of pravastatin to limit atherosclerosis in the coronary arteries (PLAC I).
    Pitt B; Ellis SG; Mancini GB; Rosman HS; McGovern ME
    Am J Cardiol; 1993 Jul; 72(1):31-5. PubMed ID: 8517425
    [TBL] [Abstract][Full Text] [Related]  

  • 30. EEC letter. How the Dutch bypass bureaucracy.
    Hugenholtz PG
    Br J Hosp Med; 1978 Jun; 19(6):605. PubMed ID: 307970
    [No Abstract]   [Full Text] [Related]  

  • 31. A new approach to clinical decision-making in coronary artery disease: observations on subsets within the Duke University Data Bank.
    Peter RH; Harris PJ; Rosati RA
    Adv Cardiol; 1980; 27():199-210. PubMed ID: 7004125
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Percutaneous coronary intervention in the Netherlands: preservation of cardiovascular care and expertise in the patient with coronary artery disease through regional engagement.
    de Vries AG
    Neth Heart J; 2006 May; 14(5):201-202. PubMed ID: 25696631
    [No Abstract]   [Full Text] [Related]  

  • 33. Percutaneous coronary intervention in the Netherlands: preservation of cardiovascular care and expertise in the patient with coronary artery disease through regional engagement: Comment.
    van der Graaf Y
    Neth Heart J; 2006 May; 14(5):202. PubMed ID: 25696632
    [No Abstract]   [Full Text] [Related]  

  • 34. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS).
    Jukema JW; Bruschke AV; van Boven AJ; Reiber JH; Bal ET; Zwinderman AH; Jansen H; Boerma GJ; van Rappard FM; Lie KI
    Circulation; 1995 May; 91(10):2528-40. PubMed ID: 7743614
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pravastatin for lowering lipids.
    Adams SP; Alaeiilkhchi N; Tasnim S; Wright JM
    Cochrane Database Syst Rev; 2023 Sep; 9(9):CD013673. PubMed ID: 37721222
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Atorvastatin. A review of its pharmacology and therapeutic potential in the management of hyperlipidaemias.
    Lea AP; McTavish D
    Drugs; 1997 May; 53(5):828-47. PubMed ID: 9129869
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pravastatin. A reappraisal of its pharmacological properties and clinical effectiveness in the management of coronary heart disease.
    Haria M; McTavish D
    Drugs; 1997 Feb; 53(2):299-336. PubMed ID: 9028747
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Regression growth evaluation statin study (REGRESS): study design and baseline characteristics in 600 patients. The REGRESS Research Group.
    Barth JD; Zonjee MM
    Can J Cardiol; 1992 Nov; 8(9):925-32. PubMed ID: 1486543
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of eicosapentaenoic acid on cardiovascular events in Japanese patients with hypercholesterolemia: rationale, design, and baseline characteristics of the Japan EPA Lipid Intervention Study (JELIS).
    Yokoyama M; Origasa H;
    Am Heart J; 2003 Oct; 146(4):613-20. PubMed ID: 14564313
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Preventive effect of pravastatin on restenosis following coronary angioplasty: prospective randomized trial].
    Iwasaki K; Kusachi S; Hina K; Yamasaki S; Nishiyama O; Takaishi A; Kita T; Taniguchi G
    J Cardiol; 1995 Jan; 25(1):15-21. PubMed ID: 7877098
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.